RachelM.LaymanMD

PubMed

• Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose ...
  E Claire Dees, Samuel Suzuki, Sarah C Mutka, Brian F Sullivan, Igor Gorbatchevsky, Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht,...> ;The Lancet. Oncology. 2024 Apr 1
• Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
  Faina Nakhlis, Samuel M Niman, Naoto T Ueno, Elizabeth Troll, Sean Ryan, Eren Yeh, Laura Warren, Jennifer Bellon, Beth Harrison, Toshiaki Iwase, H T Carisa Le-Petross,...> ;Breast Cancer Research and Treatment. 2024 Apr 1
• Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.
  Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Adam Brufsky, Rachel M Layman, Hope S Rugo> ;Future Oncology. 2024 Mar 27
• Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language ...
  Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Tiah Tomlin-Harris, Hope S Rugo, Rachel M Layman, Adam Brufsky> ;Future Oncology. 2024 Mar 22
• A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
  Cescon, D., Hilton, J., Morales Murilo, S., Layman, R., Pluard, T., Yeo, B., Park, I., Provencher, L., Kim, S., Im, Y., Wyce, A., Krishnatry, A., Hicks, K., Zhang, Q.,...> ;Clinical Cancer Research. 2024 Jan 17
• Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
  Qaio, W., Shen, Y., Raghavendra, A., Mouabbi, J., Tripathy, D., Layman, R.> ;The Oncologist. 2024 Mar 4
• Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.
  Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo> ;Cancers. 2023 Nov 2
• Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron ...
  Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Adam Brufsky> ;International Journal of Cancer. 2024 Feb 15
• Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
  Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Adam Brufsky> ;The Oncologist. 2023 Oct 3
• Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
  Jason A Mouabbi, Akshara Singareeka Raghavendra, Roland L Bassett Jr, Matthias Christgen, Lavinia Middleton, Mediget Teshome, Azadeh Nasrazadani, Gabriel Hortobagyi, A...> ;European Journal of Cancer. 2023 Sep 1
• 3 citations
  Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Th...
  Jason A Mouabbi, Akshara Singareeka Raghavendra, Roland L Bassett Jr, Amy Hassan, Debasish Tripathy, Rachel M Layman> ;JAMA Network Open. 2023 May 1
• 2 citations
  A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
  Clinton Yam, Elizabeth A Mittendorf, Haven R Garber, Ryan Sun, Senthil Damodaran, Rashmi K Murthy, David Ramirez, Meghan Karuturi, Rachel M Layman, Nuhad Ibrahim, Gaia...> ;Breast Cancer Research and Treatment. 2023 Jun 1
• Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
  Nour Abuhadra, Ryan Sun, Roland L Bassett Jr, Lei Huo, Jeffrey T Chang, Mediget Teshome, Alyson R Clayborn, Jason B White, Elizabeth E Ravenberg, Beatriz E Adrada, Ros...> ;Investigational New Drugs. 2023 Jun 1
• 3 citations
  Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer.
  Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M Layman, Adam Brufsky> ;Breast. 2023 Jun 1
• 2 citations
  Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database ana...
  Hope S Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Massimo Cristofanilli, Mylin A Torres, Giuseppe Curigliano, Richard S F...> ;Future Oncology. 2023 Mar 1
• Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
  Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo> ;Frontiers in Oncology. 2023 Jan 1
• 5 citations
  Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies.
  Jason A Mouabbi, Akshara Singareeka Raghavendra, Roland L Bassett Jr, Amy Hassan, Debu Tripathy, Rachel M Layman> ;NPJ Breast Cancer. 2022 Dec 20
• 2 citations
  Inclusion of premenopausal women in breast cancer clinical trials.
  Kelsey L Corrigan, Ramez Kouzy, Joseph Abi Jaoude, Roshal R Patel, Rachel M Layman, Sharon H Giordano, Wendy A Woodward, Benjamin D Smith, Simona F Shaitelman, Ethan B...> ;Breast. 2022 Dec 1
• 27 citations
  Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
  Hope S Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Massimo Cristofanilli, Mylin A Torres, Giuseppe Curigliano, Richard S F...> ;NPJ Breast Cancer. 2022 Oct 11
• 1 citations
  ASO Visual Abstract: Long-Term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement.
  Adrienne N Cobb, Kevin Diao, Mediget Teshome, Anthony Lucci, Naoto T Ueno, Michael Stauder, Rachel M Layman, Henry M Kuerer, Wendy A Woodward, Susie X Sun> ;Annals of Surgical Oncology. 2022 Dec 1
• 2 citations
  Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement.
  Adrienne N Cobb, Kevin Diao, Mediget Teshome, Anthony Lucci, Naoto T Ueno, Michael Stauder, Rachel M Layman, Henry M Kuerer, Wendy A Woodward, Susie X Sun> ;Annals of Surgical Oncology. 2022 Oct 1
• 14 citations
  Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the se...
  Min Jin Ha, Akshara Singareeka Raghavendra, Nicole M Kettner, Wei Qiao, Senthil Damodaran, Rachel M Layman, Kelly K Hunt, Yu Shen, Debu Tripathy, Khandan Keyomarsi> ;International Journal of Cancer. 2022 Jun 15
• 25 citations
  Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
  Jason A Mouabbi, Amy Hassan, Bora Lim, Gabriel N Hortobagyi, Debasish Tripathy, Rachel M Layman> ;Breast Cancer Research and Treatment. 2022 Jun 1
• 9 citations
  Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.
  Debra Patt, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M Layman, Adam Brufsky> ;Clinical Breast Cancer. 2022 Aug 1
• 3 citations
  Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
  Rachel M Layman, Heather Lin, Angelica M Gutierrez Barrera, Meghan S Karuturi, Clinton Yam, Banu K Arun> ;Cancer Medicine. 2022 Mar 1
• Join now to see all